MRI Danger: Gadolinium Liquid May Cause Severe Reactions Such As Nephrogenic Systemic Fibrosis
In 1988 the FDA approved the use of Gadolinium for use as a contrast agent in MRI's. Contrast agents help in enhancing the clarity of MRI images. Gadolinium bonds with damaged or diseased tissues giving doctors a much clearer picture of organs that they would without. On June 8, 2006 the FDA issued a warning that Gadolinium may be linked to Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD). NSF & NFD patients may have one or more of the follow conditions: Redded skin patches or rashes Calcification (tightening) of muscle, skin and tendons Muscle weakness Thickening of skin...
More
Page:
1
